Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Episode 3 – COVID-19 – Implications in the Management of Patients with T2D and CVD

    Episode 3 – COVID-19 – Implications in the Management of Patients with T2D and CVD

    FromKnow Diabetes by Heart™ Professional Education Podcast Series

    Start listeningView podcast show

    Episode 3 – COVID-19 – Implications in the Management of Patients with T2D and CVD

    FromKnow Diabetes by Heart™ Professional Education Podcast Series

    ratings:
    Length:
    28 minutes
    Released:
    Apr 27, 2020
    Format:
    Podcast episode

    Description

    Studies on COVID-19 are revealing that patients diagnosed with COVID-19 and who have type 2 diabetes and history of cardiovascular disease are showing increased complications. Listen to Dr. Anne Peters, an endocrinology, diabetes and metabolism specialist and Dr. Diana Issacs, an endocrine clinical pharmacy specialist discuss tackling COVID-19 in their practices, including telehealth tips on getting started, treatment plan considerations, and ways to help patients prepare.
    Released:
    Apr 27, 2020
    Format:
    Podcast episode

    Titles in the series (32)

    The American Heart Association and the American Diabetes Association are excited to announce a new podcast series for healthcare professionals. Know Diabetes by Heart™ Professional Education Podcast Series focuses on the link between cardiovascular disease (CVD) and type 2 diabetes (T2D). The series will consist of relevant cutting-edge topics such as up-to-date standards of care, guidelines and their implications for T2D and CVD, and approaches to shared decision making—among others. The American Heart Association’s and the American Diabetes Association's Know Diabetes by Heart Professional Education™ Podcast Series is brought to you by founding sponsors, Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance and Novo Nordisk, and national sponsors, Sanofi, AstraZeneca, and Bayer.